Mylan secures victory in another EpiPen case

A federal Kansas judge has dismissed a pharmacy operator’s putative class action accusing Mylan and Pfizer of illegally monopolising the market for epinephrine auto-injectors used to treat severe allergic reactions.


Get unlimited access to all Global Competition Review content